Q2 EPS Estimates for Vigil Neuroscience Raised by Wedbush

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Analysts at Wedbush raised their Q2 2025 earnings per share (EPS) estimates for shares of Vigil Neuroscience in a research report issued on Wednesday, May 7th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.39) per share for the quarter, up from their prior estimate of ($0.43). Wedbush has a "Outperform" rating and a $13.00 price objective on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. Wedbush also issued estimates for Vigil Neuroscience's Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.70) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at ($0.17) EPS.

Other analysts also recently issued research reports about the stock. HC Wainwright lowered their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, William Blair upgraded shares of Vigil Neuroscience to a "strong-buy" rating in a report on Thursday, April 24th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Vigil Neuroscience currently has a consensus rating of "Buy" and an average target price of $16.25.

View Our Latest Research Report on VIGL

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL traded up $0.13 during midday trading on Monday, hitting $2.45. 15,287 shares of the company's stock traded hands, compared to its average volume of 475,934. The firm's fifty day moving average price is $1.94 and its two-hundred day moving average price is $2.28. Vigil Neuroscience has a twelve month low of $1.31 and a twelve month high of $6.06. The company has a market cap of $114.35 million, a PE ratio of -1.18 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04.

Institutional Investors Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC increased its stake in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Vigil Neuroscience during the 4th quarter worth about $83,000. Barclays PLC raised its position in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after acquiring an additional 19,436 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its position in shares of Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after buying an additional 49,000 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

See Also

• Five stocks we like better than Vigil Neuroscience
• How to find penny stocks to invest and trade 
• Alibaba's Earnings Just Changed Everything for the Stock
• Value Investing: Is it a Good Strategy in 2022? Hint: Always
• Lockheed Martin: A Top Defense Pick in 2025
• What is the Hang Seng index?  
• If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly

Should You Invest $1,000 in Vigil Neuroscience Right Now?

Before you consider Vigil Neuroscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.

While Vigil Neuroscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report